1
Institut de Recherche sur les Vaccins et l'Immunothérapie des Cancers et du Sida and the Laboratoire d'Oncologie et Virologie Moléculaire, Faculté de Médecine René Descartes at the Centre Biomédical des Saints-Pères,
Université Paris 5, 45 Rue des Saints-Pères, 75006 Paris, France.
2
Instituto de Pesquisa en Immunoterapia de Pernambuco and the Laboratorio de Immunologia Keizo Asami,
Universidade Federal de Pernambuco, 50670-901 Recife, Brazil.
We present the results of a preliminary investigation of the efficacy of a therapeutic dendritic cell (DC)-based vaccine for HIV-1. We immunized 18 chronically HIV-1-infected and currently untreated individuals showing stable viral loads for at least 6 months with autologous monocyte-derived DCs loaded with autologous aldrithiol-2-inactivated HIV-1. Plasma viral load levels were decreased by 80% (median) over the first 112 d following immunization. Prolonged suppression of viral load of more than 90% was seen in 8 individuals for at least 1 year. The suppression of viral load was positively correlated with HIV-1-specifc interleukin-2 or interferon--expressing CD4+ T cells and with HIV-1 gag−specific perforin-expressing CD8+ effector cells, suggesting that a robust virus-specific CD4+ T-helper type 1 (TH1) response is required for inducing and maintaining virus-specific CD8+ effectors to contain HIV-1 in vivo. The results suggest that inactivated whole virus−pulsed DC vaccines could be a promising strategy for treating people with chronic HIV-1 infection.
MORE ARTICLES LIKE THIS
These links to content published by NPG are automatically generated.
-expressing CD4+ T cells and with HIV-1 gag−specific perforin-expressing CD8+ effector cells, suggesting that a robust virus-specific CD4+ T-helper type 1 (TH1) response is required for inducing and maintaining virus-specific CD8+ effectors to contain HIV-1 in vivo. The results suggest that inactivated whole virus−pulsed DC vaccines could be a promising strategy for treating people with chronic HIV-1 infection.
